Switching From Semaglutide to Tirzepatide
Two molecules, four brands, no single schedule. Find your exact brand, then keep every brand on one timeline.
Quick answer
Semaglutide and tirzepatide are different medicines, and each is sold under two brands with their own FDA dose ladders, so there is no one-to-one conversion, not even between Ozempic and Wegovy. Identify your exact brand and dose first. MeAgain then keeps every brand on one continuous timeline through the switch.
Semaglutide and tirzepatide are two different medicines, so there is no official one-to-one conversion between them. Semaglutide comes as Ozempic and Wegovy, tirzepatide as Mounjaro and Zepbound, and every brand has its own FDA dose ladder. There is not even one semaglutide schedule, since Ozempic and Wegovy differ, so identify your exact brand before reading any dose. Whichever brands you are moving between, what does not reset is everything behind you. In MeAgain your weight trend, logged side effects, and dose dates stay on one timeline no matter which brand you are on, so you can watch the old brand's levels ease off and the new one build on the estimated medication-levels graph, and see whether a rough first week is the dose or just the switch. That record is the log you bring to your prescriber. 500K people track their GLP-1 with MeAgain, rated 4.8 stars across 23K App Store ratings.
Bottom line: This page is education, not medical advice. Medication choice, dose changes, and your start date belong with your prescriber or a licensed clinician. MeAgain works with any GLP-1, branded or compounded, wherever it is prescribed.
Key takeaways
There is not even one semaglutide schedule to convert from: Ozempic runs to 2 mg and Wegovy to 2.4 mg (7.2 mg Wegovy HD for some adults), while the tirzepatide brands, Mounjaro and Zepbound, both run from 2.5 mg to 15 mg. Different scales, no one-to-one conversion, so identify your exact brand and dose first.
The label starts both tirzepatide brands at 2.5 mg for the first four weeks so your body can adjust, which is why side effects you had already settled past can come back for a few weeks after the switch. That is expected, not a setback.
Switching does not empty your system overnight. Semaglutide leaves slowly, over about five weeks from a roughly one-week half-life, while tirzepatide clears in about 25 days, so whichever way you switch the two overlap rather than trading off in a day.
Call your prescriber the same day for severe or lasting stomach pain, vomiting that will not stop, or yellowing of the skin or eyes. These are not part of a normal switch and need attention right away, whichever medicine you are on.
Tracking shots, side effects, weight, and food on one timeline carries your whole semaglutide history into tirzepatide, so you and your prescriber can see how your own body responded before and after, no matter which brand you are on.
How MeAgain Tracks You From One Brand to the Next
01Watch One Brand Fade and the Next Build
Because semaglutide and tirzepatide leave the body at different speeds, this switch is a gradual overlap rather than a clean handoff, no matter which brands you are moving between. Your semaglutide brand keeps easing out for weeks while your new tirzepatide brand, Mounjaro or Zepbound, climbs from 2.5 mg. The estimated medication-levels graph draws both on one timeline once you tell it your exact brand and dose. It is an estimate for tracking and education, not a dosing tool, but it makes an otherwise invisible transition legible: where each medicine sits this week, and whether a rough day is the new dose climbing or the old one still fading. Set your brand and dose, and the curve redraws around that brand's own schedule instead of a generic one.
02Rate Returning Symptoms on One Simple Scale
Tirzepatide opens at 2.5 mg and steps up, so the first weeks can bring back symptoms you had already outlasted on your semaglutide brand. Since the common side effects overlap heavily between the two medicines, brochure-to-brochure comparison tells you little; your own before-and-after tells you almost everything. MeAgain tracks the 18 most common GLP-1 side effects plus unlimited custom symptoms, each on a 0 to 10 severity slider with the date, so a rough patch becomes a line you can watch settle rather than a blur. That record separates an ordinary re-adjustment from something worth a call, and it hands your prescriber a concrete reading, which symptom, how strong, and when it eased, instead of a general impression.
03One Weight Line Across Every Brand
Weight wobbles early in any switch for reasons unrelated to the new brand: water shifts, one heavy week, the 2.5 mg tirzepatide starting dose. So the trend across weeks tells you far more than a single morning on the scale. MeAgain keeps your weight on one continuous line no matter how many brands you move between, so your semaglutide months and your new tirzepatide weeks share one chart and the low starting dose reads as a dip in context rather than a loss. A dose reset is not a progress reset. Because the line never restarts when the brand on the label changes, everything you logged stays part of the picture and a real plateau is easy to spot and raise with your prescriber.
04Bring the Record, Whichever Brands You Moved Between
What helps most at the next appointment is not a conversion number, because none exists, not even between the two semaglutide brands. It is your own record: your exact brand and last dose, how long you held each step, which side effects you felt and how strong, and how your weight actually moved. MeAgain keeps all of it on one timeline, so you arrive with what you tracked instead of rebuilding months from memory. The app does not choose your medicine or your dose, that stays your prescriber's call, and it does not replace the conversation. What it does is start the plan from where you actually are, a real brand and a real dose, rather than a molecule name or a chart that was never real.
Semaglutide to Tirzepatide: What Actually Changes, and What Does Not
First, find your exact brand
Semaglutide is sold as Ozempic and Wegovy; tirzepatide is sold as Mounjaro and Zepbound. That matters because there is no single semaglutide dose and no single tirzepatide dose. Each brand has its own FDA label ladder, and even the two semaglutide brands do not match: Ozempic tops out at 2 mg, Wegovy at 2.4 mg. So the useful starting point is not the molecule name but your exact brand and current dose. Everything downstream, reading the ladders, understanding clearance, planning the switch, depends on knowing which brand you are actually on. If you are not sure, your pharmacy label or your prescriber can confirm it.
Why there is no one-to-one dose conversion
There is no official one-to-one conversion between semaglutide and tirzepatide, and there is not even a clean map within a molecule, because Ozempic and Wegovy do not match each other. Ozempic tops out at 2 mg, Wegovy's standard maintenance is 2.4 mg with an alternative 1.7 mg step and a 7.2 mg Wegovy HD maximum for some adults, and both tirzepatide brands run 2.5 mg to 15 mg. A dose of one is not the same amount of the same thing as a dose of another, and the numbers are not a ranking you can read across.
Any chart that matches a semaglutide dose to an equivalent tirzepatide dose is inventing a figure the labels never set. Your prescriber picks your tirzepatide starting dose from your history, your tolerance, and your goals, not from arithmetic. The label ladders below stand as separate facts, one per brand.
Official label schedules shown side by side. Rows are not equivalent doses and should not be read across. These are separate label schedules, not a switching instruction. Use the start date and dose your prescriber gave you.
Ozempic dose ladder (semaglutide)
Dose steps from the FDA Ozempic (semaglutide) prescribing information via DailyMed, Dosage and Administration, Section 2.2. Injection schedule only, and not a switching instruction.
| Dose step | Time at this step | Role in the label schedule |
|---|---|---|
| 0.25 mg | 4 weeks | Initiation dose for treatment start; not a maintenance dose. |
| 0.5 mg | at least 4 weeks | First maintenance dosage, reached after 4 weeks on 0.25 mg. The label's recommended maintenance dosages are 0.5 mg, 1 mg, and 2 mg. |
| 1 mg | at least 4 weeks | A maintenance dosage; may be reached after at least 4 weeks on 0.5 mg if additional glycemic control is needed. |
| 2 mg | maintenance | Highest maintenance dosage; the maximum recommended dosage is 2 mg once weekly. |
Wegovy dose ladder (semaglutide)
Dose steps from the FDA Wegovy (semaglutide) prescribing information, revised June 2026, Dosage and Administration, Section 2.2 (Wegovy Injection); Dosage Forms and Strengths, Section 3. Injection schedule only, and not a switching instruction.
| Dose step | Time at this step | Role in the label schedule |
|---|---|---|
| 0.25 mg | weeks 1 to 4 | Starter dose to build tolerance; not intended for weight loss. |
| 0.5 mg | weeks 5 to 8 | Scheduled increase after 4 weeks on 0.25 mg. |
| 1 mg | weeks 9 to 12 | Scheduled increase after 4 weeks on 0.5 mg. |
| 1.7 mg | weeks 13 to 16, or week 17 onward (maintenance) | A labeled maintenance dosage for weight management; the label lists either 2.4 mg (recommended) or 1.7 mg once weekly, based on how well it works and is tolerated. It is also the last step before 2.4 mg. |
| 2.4 mg | week 17 onward (maintenance) | Recommended maintenance dosage for weight management; the label also allows 1.7 mg once weekly as the alternative maintenance dosage. For adults who tolerate 2.4 mg for at least 4 weeks, the label allows an increase to a maximum of 7.2 mg once weekly (Wegovy HD) when additional weight reduction is clinically indicated. |
Mounjaro dose ladder (tirzepatide)
Dose steps from the FDA Mounjaro (tirzepatide) prescribing information via DailyMed, Dosage and Administration, Section 2.1. Injection schedule only, and not a switching instruction.
| Dose step | Time at this step | Role in the label schedule |
|---|---|---|
| 2.5 mg | 4 weeks | Treatment initiation dose; not a maintenance dose. |
| 5 mg | at least 4 weeks | Increase after 4 weeks on 2.5 mg. |
| 7.5 mg | at least 4 weeks | Increase in 2.5 mg increments after at least 4 weeks on the current dose. |
| 10 mg | at least 4 weeks | Increase in 2.5 mg increments after at least 4 weeks on the current dose. |
| 12.5 mg | at least 4 weeks | Increase in 2.5 mg increments after at least 4 weeks on the current dose. |
| 15 mg | ongoing | Maximum dosage for adults; pediatric patients 10 years and older stop at 10 mg once weekly. |
Zepbound dose ladder (tirzepatide)
Dose steps from the FDA Zepbound (tirzepatide) prescribing information, revised April 2026, Dosage and Administration, Sections 2.1 and 2.2. Injection schedule only, and not a switching instruction.
| Dose step | Time at this step | Role in the label schedule |
|---|---|---|
| 2.5 mg | 4 weeks | Treatment initiation dose; not approved as a maintenance dosage. |
| 5 mg | at least 4 weeks | First maintenance dosage, reached after 4 weeks on 2.5 mg. The label's maintenance dosages are 5 mg, 10 mg, and 15 mg. |
| 7.5 mg | at least 4 weeks | Titration step; increase in 2.5 mg increments after at least 4 weeks on the current dose. |
| 10 mg | at least 4 weeks | A maintenance dosage, reached by 2.5 mg increments after at least 4 weeks on the current dose. |
| 12.5 mg | at least 4 weeks | Titration step; increase in 2.5 mg increments after at least 4 weeks on the current dose. |
| 15 mg | maintenance | Highest maintenance dosage; the maximum is 15 mg once weekly. |
Half-life and timing facts
Half-life, time to peak level, and time to steady state are from each product's FDA label, Section 12.3. The last row is the label's own figure where the label states one, and otherwise a standard five-half-lives estimate noted in the cell. These describe one medicine's own timing; they are not a formula for overlapping two medicines.
| Timing measure | Ozempic (semaglutide) | Wegovy (semaglutide) | Mounjaro (tirzepatide) | Zepbound (tirzepatide) |
|---|---|---|---|---|
| Elimination half-life | approximately 1 week | approximately 1 week | approximately 5 days | approximately 5 to 6 days (in patients with overweight or obesity) |
| Time to peak level (Tmax) | 1 to 3 days post dose | 1 to 3 days post dose | 8 to 72 hours (median 24 hours) | 24 hours (range 8 to 72 hours) |
| Time to steady state | reached following 4 to 5 weeks of once-weekly administration | reached following 4 to 5 weeks of once-weekly administration | reached following 4 weeks of once-weekly administration | reached following 4 weeks of once-weekly administration |
| Time in the body after the last dose | present in the circulation for about 5 weeks after the last dose | present in the circulation for about 5 weeks after the last dose | essentially eliminated after about 25 days (roughly five half-lives) by the five-half-lives convention | essentially eliminated after about 25 to 30 days (roughly five half-lives) by the five-half-lives convention |
What the timing numbers mean
These are timing measures, and they differ by molecule, which is the point here. Half-life is how long your body needs to clear half a dose, and semaglutide runs slower than tirzepatide, so the fade you feel depends on which brand you are leaving. None of these figures tells you when appetite effects start or stop, which is individual. Time to peak is how soon a dose reaches its high point, and steady state is when weekly doses stop building up. Each brand's half-life calculator in the keep-reading links below walks the fade out dose by dose.
What to expect through the first weeks
The medicine changes, the weekly rhythm changes, and the dose resets to a low step even though your progress does not. Plan for a 2.5 mg opening dose on the tirzepatide side, whether that is Mounjaro or Zepbound, and a few weeks of re-adjustment. Symptoms you had settled past can resurface briefly before easing again. Whether tirzepatide quiets appetite more for you, about the same, or less, is individual, and no page can promise which.
People reach this switch from different places. Some chose it and feel hopeful; some were moved by a cost, coverage, or approved-use change they did not pick. Whichever it is, the practical response is the same: confirm your exact brands, start from your real history, give the new medicine a full adjustment window, and let your prescriber set the pace.
Switching the other way: tirzepatide to semaglutide
Reversed, from tirzepatide back to semaglutide, the same logic holds. Tirzepatide keeps leaving your body for about 25 days after your last dose, and semaglutide steps up from 0.25 mg on whichever brand, Ozempic or Wegovy, your prescriber writes and your approved use allows. There is still no conversion to read across, so the starting dose and timing come from your history, not from your tirzepatide number. The re-adjustment, the symptoms that can briefly return, and one continuous record across every brand all apply going this way too.
Bring this to your prescriber
- The medicine, dose, and date of your most recent injection
- How long you have been at your current dose
- Side effects you have had, and how strong they were
- Other medicines and supplements you take
- The new medicine, dose, and start date your prescriber sets
- What to watch for, and when to check back in
Whichever brands you and your prescriber choose, the tracking works from day one and keeps the whole story on one timeline. MeAgain works with any GLP-1, branded or compounded, wherever it is prescribed.
For educational use only; this is not medical advice. There is no official one-to-one dose conversion between these medicines. Each has its own FDA-labeled schedule, shown here as separate label facts. Only your prescriber can choose your dose and start date. Do not use this page to change, start, or stop any medication.
Sources
- FDA Ozempic (semaglutide) prescribing information via DailyMed, Dosage and Administration and Clinical Pharmacology (Sections 2.2 and 12.3)
- FDA Wegovy (semaglutide) prescribing information, revised February 2026, Dosage and Administration and Clinical Pharmacology (Sections 2.2, 12.3)
- FDA Mounjaro (tirzepatide) prescribing information via DailyMed, Dosage and Administration and Clinical Pharmacology (Sections 2.1 and 12.3)
- FDA Zepbound (tirzepatide) prescribing information, revised February 2026, Dosage and Administration and Clinical Pharmacology (Sections 2.1, 2.2, 12.3)
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM. 2021;385:503–515
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021;384:989–1002
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205–216
- Mayo Clinic: Semaglutide injection, description, dosing, and administration
- Drugs.com: Tirzepatide monograph, dosing, half-life, and administration
- American Society of Anesthesiologists: Multi-Society Clinical Practice Guidance on GLP-1 medicines and elective procedures (2024)
First You Find Your Brand. Then You Track the Real Work.
One Record Across Every Brand
Pinning down your exact brand settles where you start; the switch itself is the part that lasts. That is where a real record proves its worth, tracking each shot, the side effects, food and water, and a weight line that runs for months. Reviewers keep coming back to that once the tracking becomes routine.
This app has helped me while on Trizeptide it showed me I should have more protein and water intake and it logs all my foods I have lost about of weight using this app with medication
That is the part that carries across the switch. The molecule may change from semaglutide to tirzepatide, but the protein, water, and symptom logging that keeps the week on track stays exactly where it was.
Because MeAgain was built for the whole GLP-1 category rather than one brand, moving between Ozempic, Wegovy, Mounjaro, or Zepbound changes nothing about the tools: the shot countdown, injection-site rotation, the 0 to 10 symptom slider, five ways to log food, and a single weight line stay exactly where they were. Whether your prescriber writes semaglutide or tirzepatide, branded or compounded, the record does not start over.
What Our Users Say
“I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication. The little capybara widget is a great visual to help me know what my body needs.”
“This app does exactly what I needed with tracking shots… location, time, amount, current medication level, and reminders for the next one. That plus weight progress is all I needed, and after trying at least 5 others this was the only one that did it in a clean, logical way- and didn't cost a fortune!”
“I really love this app and how easy it is to use for my food, water, Mounjaro weekly shot and everything else. The app is totally worth the cost and it's been perfect for me.”
“I've been on my MJ journey since September 2025. Seeing my food intake has made a huge difference. Also, reviewing my shot locations has helped me remember to rotate. I have recommended this app to my friends who have also started their own journeys!”
“I love tracking water, protein and fiber on the app. It's really cool it's able to pull my weight and steps too. Add the widget to you phone screen if you do get it, I love that.”
Learn More About Switching GLP-1 Medicines
Wegovy vs Mounjaro Side Effects: Patient Guide
Learn the key differences in Wegovy vs Mounjaro side effects to help you make informed decisions about weight loss treatment options.
Switching From Semaglutide to Tirzepatide - FAQs
No, and the reason runs deeper than usual. Not only are semaglutide and tirzepatide different medicines on different scales, there is not even a clean map within a molecule, because Ozempic and Wegovy differ from each other. The semaglutide brands run 0.25 mg to either 2 mg or 2.4 mg, and both tirzepatide brands run 2.5 mg to 15 mg. Any table claiming to convert a semaglutide dose into a tirzepatide one is fiction the labels never printed, and trusting it can land you at the wrong dose. Your prescriber sets your tirzepatide starting dose from your history, your tolerance, and your goals. The label opens most people at 2.5 mg so the body can adjust.
Related pages
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.